![Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire](https://mms.businesswire.com/media/20191118005269/en/757140/5/4124560_NN_m_2c_RGB_large.jpg)
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases | Business Wire
Novo Nordisk A/S purchases B shares worth DKK 3,582 million from Novo Holdings A/S under the 2022 share repurchase programme
![Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders | Business Wire Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders | Business Wire](https://mms.businesswire.com/media/20220901005393/en/1559342/23/Forma_Therapeutics-%28002%29.jpg)